Long-term stimulation of Toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I:C treatment

Journal of Viral Hepatitis

Volumn 21, Issue 7, 2014, Pages 480-490

  Broering, R ^a   Lutterbeck, M ^a   Trippler, M ^a   Kleinehr, K ^a   Poggenpohl, L ^a   Paul, A ^a   Gerken, G ^a   Schlaak, J F ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

hepatitis C virus; interleukin 28A B; interleukin 29; primary human hepatocytes; Toll like receptors

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; INTERLEUKIN 28A; INTERLEUKIN 29; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; CYTOKINE; IMMUNOLOGICAL ADJUVANT; TLR3 PROTEIN, HUMAN;

ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS REPLICATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; IMMUNOLOGY; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; POLY I-C; TOLL-LIKE RECEPTOR 3;

EID: 84902287690     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12174     Document Type: Article

References (26)

1. Alter MJ,. Epidemiology of hepatitis C. Eur J Gastroenterol Hepatol 1996; 8 (4): 319-323.
2. Di Bisceglie AM,. Hepatitis C. Lancet 1998; 351 (9099): 351-355.
3. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
4. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
6. Marcello T, Grakoui A, Barba-Spaeth G, et al,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131 (6): 1887-1898.
7. Sheppard P, Kindsvogel W, Xu W, et al,. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4 (1): 63-68.
8. Muir AJ, Shiffman ML, Zaman A, et al,. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52 (3): 822-832.
9. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
10. Asselah T, Bieche I, Narguet S, et al,. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57 (4): 516-524.
11. Chen L, Borozan I, Feld J, et al,. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128 (5): 1437-1444.
12. Zhang X, Ma Z, Liu H, et al,. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 2012; 57 (3): 522-528.
13. Li K, Foy E, Ferreon JC, et al,. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102 (8): 2992-2997.
14. Broering R, Wu J, Meng Z, et al,. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008; 48 (6): 914-922.
15. Morello J, Cuenca L, Soriano V, et al,. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis 2010; 202 (8): 1185-1191.
16. Coccia EM, Severa M, Giacomini E, et al,. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34 (3): 796-805.
17. Onoguchi K, Yoneyama M, Takemura A, et al,. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282 (10): 7576-7581.
18. Park H, Serti E, Eke O, et al,. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012; 56 (6): 2060-2070.
19. Thomas E, Gonzalez VD, Li Q, et al,. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142 (4): 978-988.
20. Diegelmann J, Beigel F, Zitzmann K, et al,. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010; 5 (12): e15200.
21. Doyle SE, Schreckhise H, Khuu-Duong K, et al,. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44 (4): 896-906.
22. Foy E, Li K, Sumpter R Jr, et al,. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102 (8): 2986-2991.
23. Foy E, Li K, Wang C, et al,. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300 (5622): 1145-1148.
24. Ding Q, Huang B, Lu J, Liu YJ, Zhong J,. Hepatitis C virus NS3/4A protease blocks IL-28 production. Eur J Immunol 2012; 42 (9): 2374-2382.
25. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
26. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.